BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat

Reuters01-06

BRIEF-Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat

Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O:

AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS $(FSGS)$

Source text: ID:nGNX5NP1xm

Further company coverage: AKBA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601818114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601818114","market":"us","top_or_hot":-1,"title":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a></p></li></ul><p>Source text: <span>ID:nGNX5NP1xm</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a></p></li></ul><p>Source text: <span>ID:nGNX5NP1xm</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2F1STP:1","article_id":"2601818114","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601818114","pubTimestamp":1767708212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"简介-Akebia Therapeutics宣布Praliciguat 2期临床试验中首例患者接受给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9},"content_text":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS $(FSGS)$Source text: ID:nGNX5NP1xmFurther company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601818114","isCrawlerRequest":true}